Engineering Innovative Solutions for 21st Century Medicine
News Jun 30, 2009
The Wellcome Trust and the Engineering and Physical Sciences Research Council (EPSRC) have announced joint funding for four new Centres of Excellence in Medical Engineering to transform the future of healthcare.
Engineers have been at the forefront of medical innovation throughout the history of medicine, benefiting millions of people with tools such as implants and prosthetic limbs, devices to monitor the physiological state of patients, and instruments to maintain bodily functions, such as the implantable pacemaker.
As both medicine and engineering continue to advance at great pace, it is crucial that the links between these disciplines are maintained, especially with the potential for groundbreaking advances in fields such as imaging and genetics.
In the UK, the population is ageing - people are living longer thanks to modern medicine. But as we get older, our bodies need more help to support us. Medical engineering will play an important role in meeting this growing demand:
• It's estimated there are up to 4 million operations in the world each year as a result of osteoarthritis. Better techniques to diagnose osteoarthritis combined with more tailored interventions could mean a choice of earlier and less intrusive treatments for the most common cause of chronic pain;
• In 2006 in the UK, there were 130,000 hip and knee replacement operations - but demand is growing all the time as more and more people live long enough to wear out their joints. A new generation of implants will reduce the need for further replacements and painful surgery;
• New imaging technologies have the potential to predict stroke and heart attack, improve early detection of cancer, help surgeons perform less invasive operations, and even play a role in the diagnosis and treatment of psychiatric illness, potentially helping millions of people each year;
• Tissue engineering technology has the potential to use patients' own cells to correct degenerative disease, but the processes of applying these techniques needs to be practical and efficient if they are to achieve their potential.
Four interdisciplinary research teams - at Imperial College London, King's College London, University of Leeds and Oxford University - will receive a combined total of £41 million over the next five years.
The funding will help to develop integrated teams of clinicians, biomedical scientists and world-class engineers with the capacity to invent high-tech solutions to medical challenges, potentially improving thousands of patients' lives.
• Imperial College - Osteoarthritis: £11m
• KCL - Medical Imaging: £10m
• Leeds - "50 more years after 50": £11m
• Oxford - Personalized healthcare: £8m.
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE